



A Neuroscience Technology Company



**CSE : MYTC**  
Investor Presentation  
July 2022

# FORWARD LOOKING STATEMENTS




## Disclaimer

This presentation (the "Presentation") of MyndTec Corp. (the "Company") is current as of May, 30, 2022, except as otherwise provided herein. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. An investment in the Company is speculative and involves substantial risk and is only suitable for investors that are able to bear the risk of losing their entire investment. All of the information contained in this Presentation is for preliminary discussion purposes only. Final terms and conditions may change without notice and are subject to further discussion and negotiations.

Certain statements in this Presentation may constitute forward-looking information within the meaning of applicable securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "expects," "believes," "anticipates," "budget," "scheduled," "estimates," "forecasts," "intends," "plans," and variations of such words and phrases, or by statements that certain actions, events or results "may," "will," "could," "would," or "might," "be taken," "occur," or "be achieved." Certain statements, beliefs and opinions in this Presentation (including those contained in graphs, tables and charts), which reflect the Company's or, as appropriate, the Company's managements' current expectations and projections about future events, constitute forward-looking information. Forward-looking information contained in this Presentation is based on certain assumptions regarding, among other things, expected growth, results of operations, performance, industry trends and growth opportunities.

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. The Company does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. Persons receiving or reviewing this Presentation should not rely upon it as a complete overview of the business of the Company and should rely on their own investigation and due diligence. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice. You should consult your tax or legal advisor about the information contained in this Presentation.

In this Presentation, and during the course of discussions related to the evaluation of any prospective investment in the Company (the "Purpose"), the Company may disclose certain information which it deems proprietary or confidential, and may include, discoveries, ideas, concepts, know-how, techniques, designs, specifications, drawings, blueprints, diagrams, flow charts, data, costs, prices, marketing plans, goals, sales figures, revenue, profits, and other technical, financial or business information respecting existing or planned product or service offerings, including products and services to be developed or marketed by the Company (the "Information"). At all times, Information shall be deemed confidential and proprietary and subject to the restricted use of evaluating the business of the Company for the Purpose and distribution shall be prohibited, other than as provided herein.



**“MyndMove takes the burden off patients, caregivers and the healthcare system, and more importantly improves the patient’s quality of life and ability to go out into the community...”**

*Naaz Desai (Kapadia) PT, BSc PT, MSc, PhD, Post Doctoral Fellow  
KREMBIL RESEARCH INSTITUTE-UHN*

# ABOUT MyndTec

## OUR MISSION

At MyndTec our mission is to improve the quality of human life by enabling people to do more, feel better and live independently, through innovation and utilization of technology and cost-effective access to care.



## OUR VISION

- 1) Improve patient outcomes
- 2) Improve patient experience by minimizing disruption to their lives
- 3) Increase therapist & care team satisfaction
- 4) Improve ROIs for clinics & hospitals



# ABOUT MyndTec

MyndTec is a medical device technology company focused on the treatment of Stroke and Spinal Cord Injury (SCI) and other brain related disorders. Our flagship product, MyndMove™ – is an advanced Functional Electrical Stimulation (FES) technology.

## SERVICES

### Rehabilitation for Stroke & SCI

- Upper limb focus

### Functional Electrical Stimulation

- Restore movement and mobility

### Unique Protocols

- Scientifically validated to improve movement outcomes

## TECHNOLOGY

### Device – MyndMove™

- FES therapeutic device
- 8 channels for stimulation

### Software

- 30 algorithmic movement settings
- Therapist Interface capability

### Data & Dashboard

- Identified Common Use Protocols (CUP) to optimize treatment outcomes.

## DISTRIBUTION

### 3<sup>rd</sup> Party Distributors

- Focused on medical device solutions to therapists and clinicians

### Direct Sales

- MyndTec in-house team

## CHANNELS

### Outpatient Rehab Facility (ORF)

- Hospitals & Private Rehab Clinics
- VA/DOD Government System

### Inpatient Clinics

- Hospital Rehabilitation Clinics

### Home Health Agency

- Occupational or Rehab home therapy

# COMPETITIVE ADVANTAGES



MyndTec has built a solid foundation of advanced FES technology and critical corporate and technical infrastructure which act as key enablers in executing its growth strategy, adding scale and further capturing market share.

## INFRASTRUCTURE & TECHNOLOGY

### Commercialized Product

- FDA and Health Canada clearance received

### Distribution Partnerships

- North American and Global
- Adding new partners

### MyndMove™

- Flagship device
- Unique proprietary differentiation

### Secured IP Rights

- Patents:
  - 11 owned
  - 8 exclusively licensed
  - 4 in license
- Applications:
  - 3 owned
  - 5 in license

### Clinical Research Studies

- Supporting technology and patient outcome improvement

### Home Use

- Regulatory clearance for use at home with a therapist

### Relationship - KITE

- Access to KITE technology and innovation

### Cloud Connected

- Data analytics, patient connected to therapist
- Ability to remotely change & optimize treatment

### Clinical Experience

- Dozens of devices
- Hundreds of patients
- Thousands of sessions

### Pipeline

- Lower Limb
- Depression

### Data Driven Improvements


- Product enhancements
- Optimize treatment plans

# WHAT IS FES

Functional Electrical Stimulation (FES) generates muscle contractions through electrical pulses. Treatment and therapy produces measurable functional movements such as reaching and grasping.

## FES Therapy has three components:

- 1) **Patient** must be actively attempting a motor task.
- 2) **FES System** produces the intended movement which also generates the corresponding correct sensory feedback.
- 3) **Therapist** guides the limb in motion ensuring quality & correctness of movement.
  - Therapist also adjusts the stimulation according to the changes observed in the patient throughout rehabilitation



# ABOUT MYNDTEC



MyndTec is dedicated to the development and commercialization of innovative products that improve function, maximize independence and enhance the quality of life for individuals who have suffered injury to the central nervous system as a result of stroke and spinal cord injuries (“SCI”).

## MyndMove

- The first commercial product by MyndTec
- Non-invasive neuro and nervous system electrical stimulation therapeutic device
- Treating neurological diseases and injury
- Targeting markets with large, growing, global patient populations.





# NEXT GENERATION FES & MyndMove®

High Tech Bioelectronic Device + Protocols + Therapy for Moderate to Severe **Neuro-muscular Symptoms**

MyndMove non-invasive therapy stimulates the brain to form and reorganize synaptic connections to increase neuromuscular functionality (“neuroplasticity”)

Approved commercial technology product that restores voluntary movement to stroke and SCI patients



- **Positive results in refractory cases**  
(positive results in > 90% of stroke patients who have zero mobility, where other therapies have failed)
- **Non-invasive**
- **Good acceptance from patients**  
(low discomfort and short sessions)
- **Reimbursable\***  
(FDA cleared; codes for reimbursement; third party payers)

*\*Reimbursable through a mixture of codes used to target therapist times vs treatment.*

## Indicative MyndMove Breakthroughs

*Establishing a true gold standard in the treatment of paralysis*

Best-In-Class <b>Non-Invasive</b> Device	Benefits
<p>MyndMove offers the <b>most diversity</b> of grasping and/or reaching capabilities in patients including:</p> <ul style="list-style-type: none"><li>▪ Lateral Pinch    ▪ Palmar Grasp</li><li>▪ Pinch Grasp    ▪ Lumbrical Grasp</li><li>▪ Tripod Grasp    ▪ Varied Reaching Movements</li></ul> <p>MyndMove includes patented technology that achieves functional muscle contractions at <b>very low</b> stimulation intensities</p> <p>Fast slew rate and the ability to engage nerve fibers allows electrical pulses that are <b>10-15 times</b> lower in intensity than those currently available products</p>	<ul style="list-style-type: none"><li>✓ Activation of the intrinsic muscles of the hand</li><li>✓ Ability to treat severe upper limb paralysis</li><li>✓ Increase flexibility</li><li>✓ Produce various fine motor distal movement</li><li>✓ Help patients recover everyday capabilities<ul style="list-style-type: none"><li>• Write, brush teeth, pick up objects, toileting</li></ul></li><li>✓ Suitable for stroke and spinal cord injury</li><li>✓ Reduces intensity of stimulation</li><li>✓ Reduces discomfort during stimulation</li><li>✓ Patients effectively complete their therapy</li></ul>

# VIDEO BEFORE & AFTER

*World leading FES therapy - muscle stimulation through electric currents*

- *Tolerable in contrast to traditional functional electrical stimulation*
- *Personalized treatment plans to solve enormous economic & quality of life burdens*
- *Real world objects and tasks training*


*VIDEO: Before and After MyndMove Therapy*



<https://youtu.be/Dct0e1tuxKA>

# CLINICAL EVIDENCE - VOLUNTARY MOTION

Multiple studies demonstrate substantial improvement in voluntary movement over control cohort.



## Upper extremity Fugl-Meyer (UE-FMA)

- All patients in the FES Therapy group realized a clinically significant gain in UE-FMA.

Median gain for the FES group was **24.5 pts.**


Range as **9–48 pts.**

- Only 2 of 11 patients (18%) in the Control group realized gains of more than 6 points.

Median gain for the Control Group was zero (0).

# CLINICAL EVIDENCE – SIM SCORE

An indicative randomized control trial<sup>6</sup> analyzed spinal cord independence measure (SCIM), a sub-score measuring an individual's ability to take care of themselves after spinal cord injury



GROUP 1: received **80 hours** of therapies during an 8-week period

SCIM scores improved by an average of **3.2 points**

GROUP 2: received **40 hrs** of therapies incorporating MyndMove for 8-week period

SCIM scores improved by an average of **10.2 points**

\*Min score (fully dependent): 0 , Max Score: (fully independent): 20



# OUR PARTNERS



MyndTec Inc. has been fortunate to partner with a number of organizations, each of which have contributed to the development and commercialization of MyndMove™ therapy.



# CURRENT TREATMENT LOCATIONS



MyndMove™ is licensed for use in Canada and the United States.

Therapy using the MyndMove™ device is delivered by highly trained physical and occupational therapists and also licensed or certified physical therapist assistants (PTAs) and occupational therapy assistants (OTAs) under their supervision.



# MILESTONES & ACHIEVEMENTS

## Highlights

Full Year 2021-22

The logo for MyndTec, with "Mynd" in a dark grey sans-serif font and "Tec" in a teal sans-serif font. The "y" in "Mynd" has a teal dot.

### Capital Markets:

- Listing on the CSE on February 24, 2022
- Ticker Symbol: MYTC

### Technology & Partnerships:

- Signing of LBBAT distribution partnership agreement for the U.S
- Signing of strategic alliance with Fourier Intelligence for distribution in Asia

### FDA Clearance:

- MyndTec Receives FDA 510(k) Clearance for MyndMove 2.0, its Second Generation Neuromodulation Device, for Clinical & Home Use

### Strategic:

- 360° Review of:
  - Clients & Targets (Hospitals, Clinics, etc.)
  - Technology & Competitions Tech
  - Sales Process
  - Distribution Partners


# STRATEGIC PLAN

## 3 Year Strategy

2022-2024

### 5 Pillars for Growth:

- Model
- Market
- Distribution
- Training
- Tech



# REFINE BUSINESS MODEL




OBJECTIVE

Offer a solution to customers that meets both their selection criteria and procurement processes

APPROACH

Understanding what drives adoption

Recognizing procurement policies, mandates & customer sensitivities



LEVERAGE MYNDTEC’S CAPABILITY:

- Providing seamless experience - sales, review, technical and financial impact analysis, while meeting a prospect’s selection criteria and procurement requirements.
- MyndTec is able to offer:
  - **Fee for Service – pay every time device is used**
  - **Direct Equipment Sale – one time purchase**

Target Market Criteria:

- MyndTec’s target market is neurorehab clinics with a focus on patient treatment and research
- Active user in FES to enhance neuroplasticity
- Early adopters of technology



# TARGET MARKET NEEDS



## OBJECTIVE

Focus MyndTec's market penetration efforts on the gatekeepers – therapists, by addressing their challenges and needs (TTR)

## FEEDBACK SUMMARY

### Therapist Challenges:

- Ease of use: Electrode set-up time and complexity
- Complicated Protocols: bottleneck and delays
- Productivity: get patients in and out quickly, without compromising quality of treatment

} Time,  
Turns &  
ROI

### Required to Enable MyndTec to gain market traction:

Best  
Performing  
Clinics

Data Collection  
Improvements

Adjusted  
Training

## APPROACH

“It is not enough that the patient likes using MyndMove™ and is seeing results.”

Remain focused on the the patient experience:

- Efficacy of our system
- Evidence of steady improvement
- Measurable outcomes
- Improved quality of life for the patient.

First experience with MyndMove™ is critical for adoption.

Starts with easy protocols, quick setup, intensive hands-on training.

## ← Patient

1000467  
ID

Name

M

Gender

15 September 1961

Date of Birth

(Blank)

Injury Date

Practice

17-Jun-2019

First Session


04-Oct-2021

Last Session

101

Total Sessions

● Sessions ● Total Sessions



## Protocols

Select all


Bilateral

Left

Other

Right

Protocol Name	Runs	Cycles
R04: (L) Forward Reach	57	2180
R01: (L) Hand - Mouth	23	565
R08: (L) Scapular Rotation > Forward Reach	16	584
R03: (L) Side Reach	14	354
G01: (a) (L) Finger Ext. > Palmar Grasp	11	378
G05: (a) (L) Finger Ext. > Lumbrical + Palmar	6	267
R02: (L) Opposite Shoulder Reach	3	45
R05: (L) Opposite Shoulder + Lateral Reach	3	121
R04: (R) Forward Reach	2	98
C05: (L) Forward Reach + Palmar Grasp	1	18
G01: (a) (R) Finger Ext. > Palmar Grasp	1	15
G06: (a) (R) Finger Ext. > Lateral Pinch	1	12
G11: (L) Finger Ext. > Tripod Grasp	1	29
<b>Total</b>	<b>139</b>	<b>4666</b>



# REVAMP TRAINING PRACTICES

## *Simplify and improve current training practices*

Establish a less intimidating method of training, and avoid “straight to complexity” set-up and protocol education

### FEEDBACK SUMMARY

- Onboarding, training and time commitment must be shortened.
  - hours vs days
  - online vs live
- Set-up and training proficiency in a phased manner – less intimidating (baby steps)
  - 3 electrodes & 2 protocols
  - 4 electrodes & 3 protocols

### ONBOARDING PRIORITIES

- Our goal is smooth onboarding experience
- Easy set-up
- Focused on quality of treatment
- Ensure a very positive first experience

***Be a trusted resource on FES and provider of choice for leading Hospitals, Clinics and the Therapist Community***

# ESTABLISH SALES & DISTRIBUTION



## 3 Key Focus Areas of MyndTec's Sales Strategy

### ENGAGE 3<sup>rd</sup> PARTY DISTRIBUTORS

- Agent model offers low capex expansion
- Maximize access to target market in multiple jurisdictions and channels:
  - Rehab Clinics
  - VA Clinics
  - Hospital Networks
  - Home Care
  - University Research Centers

### SELECTIVE REGIONAL EXPANSION

Build out high profile locations in select top North American markets:

- Michigan
- Ohio
- Massachusetts
- Illinois
- Select Canadian cities
- Virginia


### GROW GLOBAL DISTRIBUTOR NETWORK

- Establish relationships with leading
  - global health care networks,
  - medical device distributors,
  - technology focused care/rehabilitation partners
- Target leaders in their markets

**Build a cost effective distribution platform, to expand MyndTec's presence in the US & Canada, while partnering with leading global networks**

# DISTRIBUTION MODEL OVERVIEW

## Pilot-to-Commercial Partnership Model



**Test & Feedback | Report | Validation = ROI**



# GLOBAL DISTRIBUTION PARTNERSHIP



## Fourier Intelligence Inks Strategic Alliance Partnership with MyndTec Inc.

March 23, 2022

*The award-winning Canadian MyndMove™ therapy from MyndTec Inc. joins SoftBank-backed rehab robotics leader Fourier Intelligence's network of partners*



This partnership will focus on the distribution of MyndMove™, a non-invasive functional electrical stimulation-based intervention, to the ever-expanding global network of Fourier Intelligence.

Fourier  
Intelligence™



Fourier's global network spans over 50 countries to ensure a broad market outreach for innovative technologies. With joint laboratories with some of the top research institutes in the world such as ETH Zürich, University of Melbourne, and Shirley Ryan AbilityLab in Chicago, Fourier is set to chart the new frontier of innovative medical technologies.

**"Our partnership with MyndTec Inc. signifies yet another successful strategic collaboration with market leaders to offer innovative and clinically effective technology for our patients globally,"** said Zen Koh, Co-Founder and Global HQ CEO of Fourier Intelligence. **"MyndMove™, an electrical stimulation-based intervention, integrates perfectly into Fourier's RehabHub™ solution and complement our existing product/technology portfolio. Fourier will continue our investment into more of such joint technological developments to better provide highly integrated intelligent rehabilitation technologies to empower clinicians and patients."**

# US DISTRIBUTION PARTNERSHIP



## MyndTec Enters In Exclusive Distribution Agreement with LBB Applied Technology (LBBAT)

**September 29, 2021**

LBBAT has the exclusive right to market and distribute the MyndMove™ device:

1. in the State of Michigan;
2. to all healthcare facilities operating in the State of Michigan; the VA Polytrauma Rehabilitation Centers and the Polytrauma Transitional Rehabilitation Center Programs located in Palo Alto, CA; San Antonio, TX; Minneapolis, MN; Richmond, VA; and Tampa, FL; the Walter Reed National Military Medical Center in Bethesda, MD; the Ascension Hospital System;
3. any additional hospital systems the parties may agree (the "Exclusive Customers")

### About LBB

Life Beyond Barriers Applied Technology is a division of Life Beyond Barriers Rehabilitation Group, which operates two outpatient rehabilitation facilities in Michigan. The clinics utilize leading technology as part of their patient therapy and were early adopters and high users of MyndMove™.

## MyndMove™ Approved by Veteran Affairs Hospital Network Supplier List

**October 1, 2021**

Completed and successfully received certification


Vetted, reviewed and approved as trusted supplier of medical device to Veteran Affairs health networks.

With 9 million veterans to serve, the VA is the largest healthcare system in the U.S. and is comprised of hundreds of hospitals, medical centers, clinics and more

Offers opportunity and access to leading, high profile, innovative clinics focused on Veterans Health:

## *Reestablish innovation as a core principal focus*

Derisk and lessen the dependence of Company on MyndMove™, and diversify into additional revenue streams



***Innovation can expand MyndTec's offering, add new and diverse potential sources of revenue and allow new growth opportunities***

# EXPAND PORTFOLIO – LICENSING

Actively exploring numerous highly effective and complementary technologies available from reputable global groups.

## Primary Opportunities of Focus:

- Wearable garments with embedded sensors
- Dry electrodes for integration into garments
- Lower body stimulation technology for Foot Drop
- Hand and arm mobility

## Areas of Interest for FES:

- Major Depression Disorder
- Peripheral Artery Disease (PAD)
- Stem Cell and Regenerative Medicine



# COMPETITIVE LANDSCAPE



## NeuroMetrix Inc.

Ticker: NURO  
Market Cap: \$28M  
Sales: \$8.4M



Core Product: DPNCheck®  
Other: ADVANCETM System, Quell®

Sales Model: In-house and 3<sup>rd</sup> Party

## ReWalk Robotics Ltd.

Ticker: RWLK  
Market Cap \$62M  
Sales: \$5.5M



Core Product: ReWalk™ Personal 6.0  
Other: The ReStore™ Soft Exo-Suit

Sales Model: In-house and 3<sup>rd</sup> Party

## APYX Medical

Ticker: APYX  
Market Cap: \$280M  
Sales: \$52M



Core Product: Renuvion®  
Other: J-Plasma®, Cool-Coag

Sales Model: In-house and 3<sup>rd</sup> Party

## Zynex Inc.

Ticker: ZYXI  
Market Cap: \$283M  
Sales: \$137M



Core Product: NextWave  
Other: NeuroMove, InWave, Patient Monitoring

Sales Model: In-house and 3<sup>rd</sup> Party

## Inspire Medical Systems Inc

Ticker: INSP  
Market Cap: \$4.5B  
Sales: \$262M



Core Product: Inspire

Sales Model: In-house, Hospitals and Direct-to-consumer

## iRhythm Technologies Inc.

Ticker: IRTC  
Market Cap: \$4B  
Sales: \$341M



Core Product: Zio Service  
Other: Zio AT XT

Sales Model: In-house




# EXPAND PORTFOLIO – KITE DEVELOPMENT



## The KITE Research Institute UHN

*The research arm of the Toronto Rehabilitation Institute, KITE is a world leader in complex rehabilitation science and is dedicated to improving the lives of people living with the effects of disability, illness and aging.*



### MyndTec and Kite Collaboration:

- UHN Master Collaboration Agreement, the Company will sponsor, fund or collaborate with KITE for the research, development, testing and commercialization of FES technology
- We intend to work directly with KITE to develop new treatments, devices and products
- The Company and KITE are collaborating on an improvement to MyndMove™ to support the addition of protocols related to the treatment of lower limbs with a focus on regaining the ability to walk independently.
- Multimodal electrodes for neural precursor activation to promote neural regeneration
- Dry Electrodes for wearable garments to improve set-up time and for home use
- FES for Major Depressive Disorder (MDD)

*Identify Leading Niche Technologies*

**TARGET PROFILE**

- Geographic Location
  - Prefer Regional US, Canada, open to Global opportunities
- Niche, complementary device tech
  - FES Therapy
  - Used for Rehabilitation
  - Home or Clinic

**CHARACTERISTICS**

- Similar or smaller than MYTC
- Typically family owned, owner operated
- Requiring exit or liquidity event
- Some annual revenue \$100k – \$400k
- Growing Business with interesting growth and synergy opportunities

**PREFERED DEAL STRUCTURE**

- Leverage being a Pubco
- Typical structure:
  - 1/3 Cash,
  - 1/3 Stock,
  - 1/3 Earnout (2- 3 year)
  - 3 – 6X TTM EBITDA

*Active acquisition pipeline of 3+ potential targets.*

# CORE STRENGTHS

**MyndTec Focus: Be the preferred provider of neurotechnology solutions tailored to improving patient outcomes and therapist satisfaction.**



**Execute on a clearly outlined and strategic growth plan and translate that success into unit sales growth and significant share price appreciation.**

## Key intellectual property rights secured in the areas of:

- Functional Electrical Stimulation (FES) Therapy
- Brain Computer Interface
- Neural Regeneration - Stem Cell and FES Integrated Therapy

## Patent portfolio:

- Patents: 11 owned; 8 exclusively licensed; 4 in license discussions
- Applications: 3 owned; 5 in license discussions

## Functional Electrical Stimulation (FES) Therapy - General Rehabilitation and Depression

- Functional Electrical Stimulation System with Pulse Control (Owned; 7 patents)
- Method for Functional Electrical Stimulation Therapy (Owned; 2 patents; 3 applications)
- Functional Electrical Stimulation Device and System, and Use Thereof (Licensed; 8 patents)
- Functional Electrical Stimulation Method, use and Apparatus for Mood Alteration (License discussions; 1 patent)

## Brain Computer Interface

- Wireless Implantable Data Communication System, Method and Sensing Device (Owned; 2 patents)
- Method and System for Brain Activity Signal-based Treatment and/or Control of User Devices (License discussions; 1 patent; 5 applications)

## Neural regeneration - stem cell and FES integrated therapy

Selective, Directable Electrotaxis of Precursor Cells with Biphasic Electrical Stimulation (License discussions; 2 patents)

# CAPITAL STRUCTURE



## CAPITALIZATION INFO (JULY 01, 2022)

Stock Symbol	MYTC
Share Price	\$0.95 (June 15, 2022)
Market Capitalization	CAD \$21M
Common Shares	21.8M
- Warrants	6.0M
- Options	0.98M
Fully Diluted Outstanding	28.8M

## OWNERSHIP

Insiders & Significant		
Shareholders (Held in Escrow)	12.3M	56%
Retail Investors (FLOAT)	<u>9.5M</u>	<u>44%</u>
Total:	21.8M	100%

## LEADERSHIP

**Craig Leon** – Chief Executive Officer  
**Scott Franklin**– Chief Financial Officer  
**Ronald Kurtz** – Vice-President, Engineering  
**Yesmil Pena** - Quality Assurance Manager

## BOARD OF DIRECTORS

**Dr. Milos R. Popovic PhD** - Interim Chairman  
**Dr. Harvey Griggs** - Director  
**Richard Widgren** - Director  
**William (Bill) Jackson** – Director  
**Craig Leon** - Director

# CONTACT INFORMATION

MyndTec

CSE: MYTC

**MyndTec Inc. Head Office:**

1900 Minnesota Court, Suite 122

Mississauga, ON, CANADA

L5N 3C9

For further information visit:

***[www.myndtec.com](http://www.myndtec.com)***

**Craig Leon | CEO**

[craig.leon@myndtec.com](mailto:craig.leon@myndtec.com)

**Bill Mitoulas | Investor Relations**

[billm@venturenorthcapital.com](mailto:billm@venturenorthcapital.com)